CSIMarket Company Name, Ticker, Suppliers, else..
 

Neximmune Inc   (NEXI)

Neximmune Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

NEXI Sales vs. its Competitors Q2 2024


Comparing the current results to its competitors, Neximmune Inc reported Revenue decrease in the 2 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.18 %, recorded in the same quarter.

• List of NEXI Competitors





Revenue Growth Comparisons




Net Income Comparison

Neximmune Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 67.68 %

<<  NEXI Stock Performance Comparisons


Neximmune Inc 's Comment on Competition and Industry Peers


The company operates in a competitive landscape that includes biotechnology and biopharmaceutical firms with greater resources, technical expertise, and collaborative partnerships. Competitors are developing various immuno-oncology therapies, including genetically engineered T cell treatments such as CAR-T and TCR therapies targeting multiple myeloma and acute myeloid leukemia. Notable competitors developing CAR-T cell therapies include Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences, Inc., and Fate Therapeutics, Inc.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Neximmune Inc




Zymeworks Inc
Share Performance



+4.65%
Over The Past 5 Days
Zymeworks Inc
Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,019.360 mill. $ 37.127 mill. $ -149.992 mill.


Oncternal Therapeutics Inc
Share Performance



-89.68%
One Year
Oncternal Therapeutics Inc
Profile

Oncternal Therapeutics Inc's business model focuses on developing and commercializing novel therapies for the treatment of cancer.

More about Oncternal Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2.220 mill. $ 2.161 mill. $ -34.575 mill.


Nextcure Inc
Share Performance



-16.62%
Over The Past 5 Days
Nextcure Inc
Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 32.363 mill. $ - mill. $ -42.748 mill.


Novartis Ag
Share Performance



+15.01%
One Year
Novartis Ag
Profile

Novartis AG's business model is centered around the development, manufacturing, and marketing of innovative pharmaceutical products.

More about Novartis Ag's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 274,960.975 mill. $ 70,725.000 mill. $ 17,991.000 mill.


Nuvalent Inc
Share Performance



+0.05%
Over The Past 5 Days
Nuvalent Inc
Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 9,751.979 mill. $ - mill. $ -450.074 mill.

55 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Neximmune Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Neximmune Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.